Tetratherix Limited Annual Report 2026

01. Rising Patient ExpectationsSource: p. 28

Patients are increasingly expecting higher quality of care with a particular focus on reducing recovery times and the lower risk of complications - which is also a driver of increasing healthcare costs for patients and payers globally.

02. Need for Cost-Effective and Decentralised CareSource: p. 28

Increasing global healthcare spending and demand for healthcare services are necessitating investment in cost-effective tools and treatments, including those that can be delivered outside a traditional hospital setting, to minimise burden on the healthcare system.

03. Easier Healthcare Delivered Wherever Care HappensSource: p. 28

Consumers are taking a bigger role in healthcare choices, they are demanding safer, easier options they can use at home or assisted in outpatient settings focused on predictable performance that improves access and outcomes.

Remuneration strategy linked to group objectivesSource: p. 74

The remuneration offering is competitive based on an individual’s experience and for companies of similar size and complexity within the industry through benchmarking.

The mix of short and current TTX shareholdings encourages retention and performance across multiple years as appropriate for the lifecycle of the group.

Vesting date Exercise price Number of shares issuedSource: p. 84

Indemnity and Insurance of officersSource: p. 85

The Company has indemnified the directors and executives of the Company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium in respect of a contract to insure the directors and executives of the Company against a liability to the extent permitted by the Corporations Act 2001.The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Non-audit servicesSource: p. 85

The non-audit services disclosed in Note 31 were provided in connection with matters undertaken prior to the Company's admission to the ASX. No non-audit services were provided by the auditor following listing.

The directors are satisfied that the provision of these services is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.

Proceedings on behalf of the CompanySource: p. 85

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

Rounding of amounts The Company is an entity to which ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2026/183 applies, and accordingly, amounts in this Directors' Report have been rounded to the nearest thousand dollars, and the nearest whole dollar in the financial statements unless otherwise stated

Auditors independence declarationSource: p. 85

A copy of the auditor’s independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors’ report.

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors

William Anthony Knox Director

20 August 2026 Sydney

Note 1. General InformationSource: p. 94

The financial statements cover Tetratherix Limited as a Consolidated entity consisting of Tetratherix Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Tetratherix Limited's functional and presentation currency.

Tetratherix Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Unit 29 34-36 Ralph Street Alexandria, NSW 2015

A description of the nature of the Consolidated Entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 28 August 2026. The directors have the power to amend and reissue the financial statements.

Note 2. Material Accounting Policy InformationSource: pp. 94–98

The accounting policies that are material to the Consolidated Entity are set out below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Consolidated Entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Consolidated Entity.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Going Concern

The Group has prepared the financial statements for year ended 30 June 2026 on the going concern basis which assumes normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

For the year ended 30 June 2026, the Group incurred a loss of $9,320,535 (2025: $9,425,552) and incurred operating cash outflows of $2,376,614 (2025: $2,671,371). As at 30 June 2026, the Group had cash and cash equivalents of $34,364,884 (2025: $29,336,526), and net assets surplus of $32,726,762 (2025: $27,246,865).

The directors believe that:

As at 30 June 2026, the Group has $34,364,884 in cash and cash equivalents to ensure sufficient cash inflows to meet its obligations as they fall due over the next 12 months after signing date of these financial statements. Management has prepared a cash flow forecast for the next 12 months, considering expected operational inflows and outflows. Based on these forecasts, the Group expects to have adequate resources to continue in operational existence for beyond the next 12 months. As part of the IPO process, the company's prospectus outlines a detailed use of Funds from May 2025-June 2027 which demonstrates adequate funding over this period. This will continue to be reported on each quarter as part of the Company's Appendix 4C requirements. This has been supplemented by receipt of Superpower licence revenue, Industry Growth Program (IGP) grant income and May 2026 capital injection.

Basis of Preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') as appropriate for for- profit oriented entities. These financial statements also comply with IFRS Accounting Standards as issued by the International Accounting Standards Board ('IASB').

Historical Cost Convention The financial statements have been prepared under the historical cost convention, except for right of use assets and lease liabilities, and financial liabilities at fair value through profit or loss.

Critical Accounting Estimates The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Consolidated Entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.

Parent Entity Information

In accordance with the Corporations Act 2001, these financial statements present the results of the Consolidated entity only. Supplementary information about the parent entity is disclosed in note 35.

Principles of Consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Tetratherix Limited ('Company' or 'parent entity') as at 30 June 2026 and the results of all subsidiaries for the year then ended. Tetratherix Limited and its subsidiaries together are referred to in these financial statements as the 'Consolidated Entity'.

Subsidiaries are all those entities over which the Consolidated Entity has control. The Consolidated Entity controls an entity when the Consolidated Entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Consolidated Entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the Consolidated Entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Consolidated Entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Where the Consolidated Entity loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The Consolidated Entity recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

Revenue recognition

The Consolidated Entity recognises revenue as follows:

Government Grants Government grants relating to costs are deferred and recognised in profit or loss over the period necessary to match them with the costs that they are intended to compensate. Refundable tax offsets received from the Australian Taxation Office (ATO), such as those under the Research and Development Tax Incentive program, are accounted for as government grants in accordance with AASB 120.

Interest Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Other Income Other revenue is recognised when it is received or when the right to receive payment is established.

Licence Fee Revenue The Company is entitled to receive licence fee payments under a research and development agreement with an external party. The Company retains ownership of the intellectual property (IP) and supports to the product development process.

The annual exclusivity arrangement comprises a combined performance obligation consisting of a right-to-access intellectual property licence together with related stand-ready obligations (including maintenance of exclusivity, regulatory support, and continued availability of technical platform support), which are not separately identifiable in the context of the contract.

Under AASB 15 Revenue from Contracts with Customers, this combined performance obligation is satisfied over time, as the customer simultaneously receives and consumes the benefits of the licence and stand-ready obligations as the Company performs. Revenue from licence fee payments is therefore recognised over the period of the licence.

Income Tax

The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:

when the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or when the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled, and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

Current and Non-Current Classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Consolidated Entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Consolidated Entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no right at the end of the reporting period to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

Cash and Cash Equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash, and which are subject to an insignificant risk of changes in value, and are held for the purpose of meeting short-term cash commitments rather than for investment purposes.

Trade and Other Receivables

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

InventoriesSource: p. 98

Raw materials, work in progress and finished goods are stated at the lower of cost and net realisable value using the standard cost method. Standard cost comprises of direct materials and delivery costs, direct labour, import duties and other taxes, an appropriate proportion of variable and fixed overhead expenditure based on normal operating capacity.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Raw materials and work in progress may have dual use, being available for consumption in either the Group's research and development activities or its manufacturing activities for commercial supply. Where inventory is identified as consumed for research and development purposes, the related cost is reclassified out of inventory and expensed to profit or loss as incurred.

PrepaymentsSource: p. 98

Prepayments comprise of amounts paid in advance for goods and services to be received in future periods and are initially recognised at the amount paid. Prepayments are not subsequently remeasured other than for impairment, and are reviewed for recoverability where there is an indication that the related goods or services will not be received.

Prepayments made in respect of property, plant and equipment represent deposits or instalments paid to suppliers prior to delivery, installation or completion of the asset, and are carried at cost until the risks and rewards of ownership transfer to the Group, at which point the amount is reclassified to the relevant class of property, plant and equipment.

Prepaid insurance premiums are recognised as an asset and expensed on a straight-line basis over the period of insurance cover to which they relate, and are classified as current or non-current based on whether the related cover period falls within twelve months of the reporting date.

Other prepayments are similarly recognised at cost and released to profit or loss as the associated goods or services are consumed or the underlying benefit expires.

Note 2. Material Accounting Policy Information (continued)Source: pp. 99–104

Joint Ventures

A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. Investments in joint ventures are accounted for using the equity method. Under the equity method, the share of the profits or losses of the joint venture is recognised in profit or loss and the share of the movements in equity is recognised in other comprehensive income. Investments in joint ventures are carried in the statement of financial position at cost plus post-acquisition changes in the Consolidated Entity's share of net assets of the joint venture. Goodwill relating to the joint venture is included in the carrying amount of the investment and is neither amortised nor individually tested for impairment. Income earned from joint venture entities reduce the carrying amount of the investment.

Property, Plant and Equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows: Leasehold improvements 10 years Plant and equipment 5-25 years Fixtures and fittings 25 years Motor vehicles 8 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Consolidated Entity. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.

Right-of-Use Assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except were included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Consolidated Entity expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Consolidated Entity has elected not to recognise a right-of-use asset and corresponding lease liability for short- term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

Intangible Assets Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

Research and Development

Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the Consolidated entity is able to use or sell the asset; the Consolidated Entity has sufficient resources and intent to complete the development; and its costs can be measured reliably. Capitalised development costs are amortised on a straight- line basis over the period of their expected benefit, being their finite life of 10 years.

Website

Significant costs associated with the development of the revenue generating aspects of the website, including the capacity of placing orders, are deferred and amortised on a straight-line basis over the period of their expected benefit, being their finite life of 10 years.

Trademarks and Patents

Significant costs associated with trademarks and patents are deferred and amortised on a straight-line basis over the period of their expected benefit, being their finite life of 10 years. The carrying amount of trademarks is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

Impairment of Non-Financial Assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

Trade and Other Payables

Trade and other payables represent liabilities for goods and services provided to the Consolidated Entity prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Contract Liabilities

Contract liabilities represent the Consolidated Entity's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the Consolidated Entity recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Consolidated Entity has transferred the goods or services to the customer.

Borrowings

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

Lease Liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Consolidated Entity's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down. Both the principal and interest components of lease repayments are classified as financing activities in the Statement of Cash Flows.

Finance Costs

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

Preference Shares

Preference shares are initially recognised at fair value, net of any transaction costs directly attributable to their issuance. They are classified as financial liabilities at fair value through profit or loss in accordance with AASB 9 Financial Instruments due to the antidilution clause resulting in the conversion rate to ordinary shares not being fixed.

Financial Liabilities

Financial liabilities in the form of convertible instruments are initially recognised at fair value, net of directly attributable transaction costs. Financial liabilities that convert into a variable number of the Company’s shares are designated at fair value through profit or loss.

Employee Benefits

Short-term employee benefits Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Other Long-Term Employee Benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Share-based payments

Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Consolidated Entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying the Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the Consolidated Entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Consolidated Entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

Fair Value Measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use.

Assets and liabilities measured at fair value are classified into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Issued Capital Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Goods and Services Tax ('GST') and other Similar Taxes Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payableto, the tax authority.

New Accounting Standards and Interpretations Not Yet Mandatory or Early Adopted Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the Consolidated Entity for the annual reporting period ended 30 June 2026. The Consolidated Entity's assessment of the impact of these new or amended Accounting Standards and Interpretations, most relevant to the Consolidated entity, are set out below.

AASB 18 Presentation and Disclosure in Financial Statements AASB 18 replaces AASB 101 and applies from 1 January 2027, with early adoption permitted; the Consolidated Entity has not early adopted. The standard changes presentation and disclosure only, with no material impact expected on the recognition or measurement of assets, liabilities, income or expenses. Key changes include five new categories in the statement of profit or loss (operating, investing, financing, income taxes and discontinued operations), two mandatory subtotals ('operating profit' and 'profit before financing and income taxes'), new disclosures for management-defined performance measures such as EBITDA, and enhanced guidance on aggregation and disaggregation of information.

The Consolidated Entity will adopt AASB 18 from 1 July 2027 and is assessing its impact on the structure of the statement of profit or loss and cash flows, management defined performance measures (MPM) disclosures, and the grouping of items currently labelled 'other'.

Operating Segments Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM have been identified as the parent entity's Board of Directors.

Earnings Per ShareSource: p. 104

Basic Earnings Per Share Basic earnings per share is calculated by dividing the profit attributable to the owners of Tetratherix Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted Earnings Per Share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

Comparative FiguresSource: p. 104

Comparatives have been realigned where necessary, to be consistent with current year presentation. There was no effect on profit, net assets, or equity.

Note 3. Critical Accounting Judgements, Estimates and AssumptionsSource: pp. 105–107

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-Based Payment Transactions The Consolidated Entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Estimation of Useful Lives of Assets The Consolidated Entity determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Lease Term The lease term is a significant component in the measurement of both the right-of-use asset and lease liability. Judgement is exercised in determining whether there is reasonable certainty that an option to extend the lease or purchase the underlying asset will be exercised, or an option to terminate the lease will not be exercised, when ascertaining the periods to be included in the lease term. In determining the lease term, all facts and circumstances that create an economical incentive to exercise an extension option, or not to exercise a termination option, are considered at the lease commencement date. Factors considered may include the importance of the asset to the Consolidated Entity's operations; comparison of terms and conditions to prevailing market rates; incurrence of significant penalties; existence of significant leasehold improvements; and the costs and disruption to replace the asset. The Consolidated Entity reassesses whether it is reasonably certain to exercise an extension option, or not exercise a termination option, if there is a significant event or significant change in circumstances.

Incremental Borrowing Rate Where the interest rate implicit in a lease cannot be readily determined, an incremental borrowing rate is estimated to discount future lease payments to measure the present value of the lease liability at the lease commencement date. Such a rate is based on what the Consolidated Entity estimates it would have to pay a third party to borrow the funds necessary to obtain an asset of a similar value to the right-of-use asset, with similar terms, security and economic environment.

Employee Benefits Provision As discussed in note 2, the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

Income Tax The Group receives government grant income under programs such as the Australian Government's Industry Growth Program (IGP), and certain related expenditure may also qualify as eligible research and development (R&D) expenditure. Management exercises judgement in estimating any R&D clawback adjustment arising from the interaction between grant funding and the Group's R&D tax incentive claim, which is finalised following lodgement of the claim for the relevant financial year and may differ from amounts estimated during the year.

Management also assesses the Group's base rate entity status for each financial year based on its income composition, in order to determine the applicable corporate tax rate for measuring the Group's income tax position. This assessment is monitored throughout the year, and the Group's eligibility for base rate entity status may change if the composition of its income changes.

Utilisation and recognition of carried-forward tax losses The Group has carried-forward tax losses available for offset against future taxable income. Utilisation of these losses in any given year is contingent on satisfying the continuity of ownership test in Division 165 of the Income Tax Assessment Act 1997, or, where this test is not met, the same business test. Judgement is required in assessing whether these tests have been satisfied in respect of losses utilised in the period, and in assessing whether it is probable that sufficient future taxable profits will be available to utilise the Group's remaining unrecognised tax losses. Where it is not considered probable that future taxable profits will be sufficient, no deferred tax asset is recognised in respect of these losses.

Deferred Income The recognition of deferred income requires judgement in determining the extent to which eligible expenditure is capitalised and the appropriate timing of income recognition in accordance with AASB 120. The majority of the deferred income is expected to be recognised beyond 12 months.

Capitalisation of Development Costs The Consolidated Entity capitalises development expenditure only where it satisfies the recognition criteria set out in AASB 138.57. Management exercises judgement in determining when a project moves from the research phase into the development phase and meets these criteria, having considered the technical feasibility of completing the intangible asset such that it will be available for use or sale, the Consolidated Entity's intention and ability to complete the asset and use or sell it, the availability of adequate technical, financial and other resources to complete development, the manner in which the asset is expected to generate probable future economic benefits, and the ability to reliably measure the expenditure attributable to the asset during its development. This assessment requires significant judgement, particularly given the early commercial stage of the Consolidated Entity and the inherent uncertainty in medical device and biomedical development programs. Should management's assessment of any of these criteria change in future periods, this may impact the amount of development expenditure capitalised or expensed as incurred.

Recognition of Raw Materials and Work in Progress as Inventory Management exercises judgement in determining that raw materials and work in progress held by the Group meet the recognition criteria for inventory under AASB 102, on the basis that these items have dual use and may be consumed either in the Group's research and development activities or in the Group's manufacturing activities for commercial supply. Where inventory is identified as having been consumed for research and development purposes, the related cost is reclassified out of inventory and expensed to profit or loss as R&D expenditure at the point of identification or consumption. This assessment of dual use, and the point at which inventory is identified as consumed for R&D rather than retained for commercial production, requires judgement and is reassessed on an ongoing basis as manufacturing activity scales.

Impairment Assessment of Capitalised Development Costs Capitalised development costs relating to the Group's Tegenix and TegenEOS (Bone Franchise) intangible assets not yet available for use are tested for impairment annually, irrespective of whether there is any indication of impairment, in accordance with AASB 136. This assessment requires management to estimate the recoverable amount of the asset, having regard to the expected future economic benefits to be derived once the related product reaches commercial availability, including the timing and probability of achieving regulatory approval and commercial launch, expected market demand, and the continued technical and commercial viability of the project. This assessment involves significant estimation uncertainty given the early commercial stage of the Consolidated Entity and the inherent risks associated with medical device development, regulatory approval and market adoption. Changes in these assumptions in future periods could result in the recognition of an impairment loss or derecognition of asset.

Classification of Cash and Cash equivalents Management exercises judgement in determining whether dollar balances held in the Company’s USD yield account meet the definition of cash and cash equivalents in AASB 107, rather than being classified as a separate financial asset. In reaching its conclusion, management considered the absence of any lock-up period, allowing funds to be accessed on demand; the balance's function in facilitating the Company's multi- currency operating and foreign exchange; the Company's practice of drawing down the balance against near-term commitments rather than holding it for investment purposes; and the short-duration, capital- stability objective of the underlying funds.

Contract Liabilities The Group recognises licence fees received under its technology licensing arrangements as a contract liability to the extent that performance obligations under the licence have not yet been satisfied. Management exercises judgement in determining the timing of revenue recognition for these arrangements, including: whether the licence and other promised deliverables (such as manufacturing supply or technical support) represent separate or combined performance obligations; whether the licence provides a right to access the Group's intellectual property over time or a right to use it at a point in time, which determines whether revenue is recognised over the licence term or upon transfer; and the extent to which milestone or variable consideration is included in the transaction price, applying the constraint under AASB 15. Changes in these judgements could materially affect the timing of revenue recognition and the carrying value of contract liabilities in future periods.

Note 4. Operating SegmentsSource: p. 108

The Group operates as a single operating segment, and its activities are not subdivided into different operating segments for internal management purposes. Accordingly, the Group does not prepare segmental financial information, as directors monitor the Group as a whole.

The operating segment information is the same information as provided throughout the financial statements and therefore not duplicated.

Major Customers During the year, the Group derived $918,151 (2025: $nil) of revenue from a single external customer under a licensing arrangement, representing approximately 24% of the Group's revenue and other income for the year. Government grant income and interest revenue are excluded from this analysis, as they do not arise from contracts with customers. As the Group operates as a single operating segment, this revenue is reported within that segment. No other external customer contributed 10% or more of the Group's revenue during the current or prior financial year.

Geographical Information All of the Group's revenue from contracts with customers ($918,151; 2025: $nil) relates to a customer domiciled in the United States. Government grant income and interest revenue, which are Australian-sourced but do not arise from contracts with customers, are excluded from this analysis, consistent with the major customers disclosure above.

Note 5. Revenue and Other IncomeSource: p. 108

Government grant income and interest revenue are recognised at a point in time. Licence fee revenue is recognised over time, over the term of the licence agreement (refer to note 19 Contract Liabilities).

Note 6. Net Fair Value Loss on Financial LiabilitiesSource: p. 108

The FY25 loss related to the conversion of SAFE notes and convertible notes to equity prior to the Group’s IPO. Refer to note 29 for fair value measurement.

Note 7. ExpensesSource: p. 109

Note 8. Income TaxSource: pp. 110–111

The above potential tax benefit for tax losses has not been recognised in the statement of financial position as the recovery of this benefit is uncertain. In addition, these tax losses can only be utilised in the future if the continuity of ownership test is passed, or failing that, the same business test is passed.

The above potential tax benefit, which excludes tax losses, for deductible temporary differences has not been recognised in the statement of financial position as the recovery of this benefit is uncertain.

Key income tax judgements and positions adopted During the half-year, the Group received government grant income under the Australian Government’s Industry Growth Program (IGP). Certain expenditure incurred in relation to the grant is also expected to qualify as eligible research and development (R&D) expenditure. Management has estimated a R&D clawback adjustment of $733,947 for the year, which may change following finalisation of the Group’s R&D tax incentive claim for the full financial year.

Management has also assessed the Group’s base rate entity status for the year ending 30 June 2026 and concluded that the Group qualifies as a base rate entity. Accordingly, a corporate tax rate of 25% has been applied in assessing the Group’s income tax position for the year.

During the year, the Group generated taxable income of $83,348, which was offset in full by tax losses carried forward from prior years, resulting in no income tax payable for the year ended 30 June 2026. Utilisation of these losses requires the Group to satisfy the continuity of ownership test in Division 165 of the Income Tax Assessment Act 1997, or, where this is not satisfied, the same business test. Management has assessed and concluded that the continuity of ownership test is satisfied, and accordingly the Group is entitled to utilise these losses against current year taxable income.

Note 9. Cash and Cash EquivalentsSource: p. 112

As at 30 June 2026, the Company held USD$2,770,853 (A$4,024,273 equivalent) in the USD Yield account. No amounts of cash and cash equivalents, including the USD Yield account, are subject to restrictions on use as at the reporting date.

Redemption proceeds from the USD Yield account are ordinarily received within 1–2 business days of a withdrawal request. This timing is consistent with the Company's classification of the balance as a cash equivalent on the basis described in Note 2.

Note 10. Other ReceivablesSource: p. 112

Allowance for expected credit losses The Consolidated Entity has recognised a loss of $nil (2025: $nil) in profit or loss in respect of the expected credit losses for the year ended 30 June 2026.

Note 11. InventoriesSource: p. 113

The accounting policy applied in respect of inventories is set out in Note 2.

Raw materials and work in progress held by the Group have dual use, being available for consumption in either the Group's research and development activities or its manufacturing activities for commercial supply. Inventory held at reporting date relates to both research and development activity and inventory held for commercial sale, and has not yet been differentiated between the two uses. Inventory identified as consumed for research and development purposes is reclassified out of inventory and expensed to profit or loss as incurred. No such amounts were expensed during the year (2025: $nil).

No write-down of inventories to net realisable value was required during the year (2025: $nil), and no inventories are pledged as security for any liabilities of the Group (2025: nil).

Note 12. PrepaymentsSource: p. 113

(i) Prepayments for property, plant and equipment are advance payments for property, plant and equipment, which represent a new balance recognised during the year and had not met the criteria for recognition as property, plant and equipment at the reporting date.

(ii) Prepaid insurance relates to insurance costs incurred in connection with the Group's initial public offering (IPO), which are expensed over the period of coverage. Insurance prepayments are classified as current or non-current based on the expected timing of utilisation.

In the comparative year, the Group reclassified $139,302 of prepaid insurance from current assets to non-current assets to reflect the timing of the expected economic benefits. The reclassification had no impact on the profit or loss.

Note 13. Property, Plant and EquipmentSource: p. 114

Reconciliation Reconciliation of the written down values at the beginning and end of the current and previous financial year are set out below:

Note 14. Right-of-Use AssetsSource: p. 115

The Consolidated Entity leases the following premises:

During the year, the Consolidated Entity recognised an increase in right-of-use assets arising from a modification of the existing office lease, which resulted in a remeasurement of the lease liability and a corresponding uplift to the right-of-use asset.

The Consolidated Entity also entered into a new lease arrangement during the year for its advanced manufacturing facility, resulting in the recognition of additional right-of-use assets and a corresponding lease liability (refer to note 22 Lease Liabilities). In connection with the new lease, the Consolidated Entity also recognised a make-good provision in respect of its obligation to restore the leased premises at the end of the lease term, with a corresponding adjustment to the right-of-use asset (refer to note 24 Provisions).

Reconciliation Reconciliation of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated Buildings

For other AASB 16 lease disclosures refer to:

note 14 for depreciation on right-of-use assets, interest on lease liabilities and other lease expenses; note 22 for lease liabilities at the reporting date; note 28 for undiscounted future lease commitments; and consolidated statement of cash flows for repayment of lease liabilities.

Note 15. Other Financial AssetsSource: p. 116

Other financial assets include restricted deposits of $819,985 (30 June 2025: $nil) held as security in relation to lease arrangements. Refer to note 32 for further details.

Note 16. IntangiblesSource: pp. 116–117

Reconciliation Reconciliation of the written down values at the beginning and end of the current and previous financial year are set out below:

Capitalised development costs relate to the Group's Tegenix and TegenEOS bone regeneration products (Bone Franchise). The carrying amount of capitalised development costs at 30 June 2026 was $1,125,730 (2025: $nil), comprising additions of $1,125,730 recognised during the year (2025: $nil). No amortisation has been recognised in respect of capitalised development costs (2025: $nil), as the Tegenix and TegenEOS assets had not reached commercial availability at reporting date. R&D costs that were not eligible for capitalisation have been expensed as incurred.

Total Research & Development of $5,062,926 (2025: $3,078,307) includes cash outlay for project specific activities, directly attributable staff, research and laboratory costs, trademarks, patent filing and upkeep. This included $2,464,170 ($1,418,723) recognised as research and development expense, $2,598,756 ($1,659,584) of employee benefits and R&D administration costs.

As these assets are not yet available for use, they are required to be tested for impairment annually in accordance with AASB 136, irrespective of whether there is any indication of impairment. No impairment loss was recognised during the year (2025: nil). Key estimates and assumptions applied in this assessment are set out in Note 3.

Note 17. Trade and Other PayablesSource: p. 117

Refer to note 28 for further information on financial instruments.

Note 18. Share Application MoniesSource: p. 117

During the period, Tetratherix received cash proceeds of $2,017,092 from directors or their related parties under the capital raise, representing subscription monies for 336,182 shares at an issue price of $6.00 per share. As at the date of this report, these shares had not yet been issued, with formal allotment subject to approval by the Board at its AGM scheduled meeting on 12 November 2026. The subscription monies received have been recorded as share application monies pending issuance, in accordance with the Company's accounting policy, and will be reclassified to issued capital upon Board approval and allotment. The Company expects to issue the shares and lodge the relevant Appendix 2A with the ASX within the timeframe required under the ASX Listing Rules following Board approval.

Note 19. Contract LiabilitiesSource: p. 118

Reconciliation Reconciliation of the movement in carrying amount at the beginning and end of the current and previous financial year are set out below:

The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied at the end of the reporting period was $3,456,570 as at 30 June 2026 (30 June 2025: $nil)

Note 20. Deferred IncomeSource: p. 119

During the year, the Group recognised deferred income in relation to government grants received under the Industry Growth Program (IGP) and the Research and Development Tax Incentive (R&D Tax Incentive).

Deferred income arises in respect of government grants received for eligible expenditure relating to capitalised development costs, property, plant and equipment, and leasehold improvements. In accordance with AASB 120 Accounting for Government Grants and Disclosure of Government Assistance, grant income relating to these assets is deferred and recognised in profit or loss on a systematic basis over the useful lives of the respective assets. Grant income associated with capitalised development costs is recognised over the useful life of the related asset, consistent with the recognition of the associated amortisation expense.

At the reporting date, the underlying capitalised costs had not yet been amortised, and accordingly the related grant income has not been recognised

Reconciliation Reconciliation of the movements in carrying amount at the beginning and end of the current and previous financial year are set out below:

Significant Accounting Judgement The recognition of deferred income requires judgement in determining the extent to which eligible expenditure is capitalised and the appropriate timing of income recognition in accordance with AASB 120. The majority of the deferred income is expected to be recognised beyond 12 months.

Note 21. BorrowingsSource: p. 120

Refer to note 28 for information on financial instruments and note 34 for related party information.

NSW Medical Device Fund The Consolidated Entity entered into a funding agreement with NSW Health Administration Corporation in October 2018. The funding is to be used for the commercialisation of TrimphDent Medical Device (Dental Bone Regeneration application).

The Consolidated Entity is not required to make any repayment of the loan until the specific project has achieved commercial success, and positive EBIT is derived from Tegenix (Dental Bone Regeneration) product sales. The loan is unsecured and the applicable interest rate is calculated using the annual Consumer Price Index (CPI).

Note 22. Lease LiabilitiesSource: p. 120

Refer to note 28 for undiscounted future lease commitments.

Note 23. Employee BenefitsSource: p. 121

Note 24. ProvisionsSource: p. 121

Lease Make Good The provision represents the present value of the estimated costs to make good the premises leased by the Consolidated Entity at the end of the respective lease terms.

Note 25. Issued CapitalSource: pp. 122–124

(1) Preference Shares At IPO, on 30 June 2025, the preference shares were converted to ordinary shares and reclassified to equity. The preference Shares were converted into ordinary shares on a 1:1 basis at an effective average conversion price of $0.60 per share. In accordance with the terms of issue, the conversion price equalled the initial issue price of each preference share. No adjustments were made to the conversion price, as the anti-dilution provisions were not triggered as no additional shares were issued during the relevant period.

(2) SAFE notes In July 2024, the Company issued Simple Agreements for Future Equity (SAFE) notes with a principal amount of $2,570,000. The SAFE notes provided holders the right to convert into a variable number of senior shares upon a qualifying equity financing or designated liquidity event. The conversion price was based on a 20% discount to the IPO price or the valuation cap of $75 million, whichever resulted in a lower price per share. For the SAFE notes, the discounted valuation cap price of $2.05 per share was applied, resulting in the issuance of 1,253,762 ordinary shares on conversion.

The conversion occurred on 20 June 2025, the day conditional approval for ASX admission was received ahead of the IPO. Upon conversion into ordinary shares of the Company, the SAFE notes were extinguished, and equity was recognised.

(3) Convertible Subscription Notes In December 2024, the Company issued convertible subscription notes with a principal amount of $8,445,000. The notes accrued interest at 8.00% per annum, capitalised until conversion.

Interest accrued to 20 June 2025 was $311,723. Holders were entitled to convert the notes into a variable number of senior shares upon the IPO or redeem for cash upon maturity or default. All note holders elected to convert to equity. The conversion price was based on a 20% discount to the IPO price or the valuation cap of$100 million, whichever resulted in a lower price per share. For the convertible notes, the discounted IPO price of $2.30 per share was applied, resulting in the issuance of 3,807,270 ordinary shares on conversion.

The conversion occurred on 20 June 2025, the day conditional approval for ASX admission was received ahead of the IPO. Upon conversion into ordinary shares of the Company, the convertible notes and accrued interest were extinguished and equity was recognised.

(4) Share Split On 1 May 2025, the shareholders approved the subdivision (share split) of each ordinary share, option, preference share, SAFE note and Convertible note of the Company on a 1-for-635 basis. All disclosed share numbers, movements and issue prices have been retrospectively adjusted to reflect the share split, presenting all figures prior to the share split as if the subdivision had occurred prior to the start of the comparative reporting period.

Shares Under Escrow The Company's restricted and voluntary shares under escrow as at 30 June 2026 are as follows:

(1)The ASX imposes mandatory escrow on specific shareholders as part of its listing rules, particularly for companies admitted under the "assets test".

(2) At the Consolidated Entity's request, the Holders have agreed to the restrictions set out above in relation to the Restricted Securities issued. The escrow period for the Restricted Securities commenced at listing on 30 June 2025.

Ordinary shares Ordinary shares entitle the holder to participate in any dividends declared and any proceeds attributable to shareholders should the Company be wound up, in proportions that consider both the number of shares held and the extent to which those shares are paid up. The fully paid ordinary shares have no par value, and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Capital Risk Management The Consolidated Entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the Consolidated Entity may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

Note 26. ReservesSource: pp. 124–125

Share-Based Payments Reserve The reserve is used to recognise the value of equity benefits provided to employees, directors and contractors as part of their remuneration, and other parties as part of their compensation for services. Refer to note 39 for movement in share-based payments reserve.

During the year ended 30 June 2026, the Company recognised a share-based payments reserve of $665,592 (2025: $nil), representing the fair value of performance rights granted to employees, directors and contractors that remained unvested at reporting date. $1.471 million of performance rights vested or were exercised during FY26. Refer share capital movements table in Note 25.

In the prior year ended 30 June 2025, all outstanding share options under the legacy employee share option plan were exercised by eligible employees, and the share-based payments reserve balance was transferred to issued capital upon exercise. The Company has retired this legacy plan and no further options will be issued under it.

Movements in Reserves Movements in the share-based payments reserve during the current year relate to the recognition of share- based payments expense of $2,136,947 in respect of performance rights granted to employees, directors and contractors during the year, which remain partially unvested at 30 June 2026. In the prior year, the movement related to the transfer of the reserve balance to issued capital upon exercise of options under the legacy employee share option plan, which has since been retired.

Reconciliation Reconciliation of the written down values at the beginning and end of the current and previous financial year are set out below:

Note 27. DividendsSource: p. 125

There were no dividends paid, recommended or declared during the current or previous financial year.

Note 28. Financial InstrumentsSource: pp. 126–128

Financial Risk Management Objectives The Consolidated entity's activities expose it to a variety of financial risks: market risk (including interest rate risk),and liquidity risk. The Consolidated entity's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Consolidated entity. The Consolidated entity uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate risk.

Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the Consolidated entity and appropriate procedures, controls and risk limits. Finance identifies and evaluates financial risks within the Consolidated entity's operating units. Finance reports to the Board on a monthly basis.

Price Risk The Consolidated entity is not exposed to any significant price risk.

Interest Rate Risk The Consolidated entity's main interest rate risk arises from long-term borrowings.

The loans outstanding with NSW Health Administration Corporation, totalling $1,899,883 (2025: $1,831,644), are principal and interest. The repayment of the loan is only contingent on the commercial success of the project.

Separately, the return earned on the Yield USD account moves with short-term USD money market rates. As at 30 June 2026 the Consolidated entity held AUD$4,024,273 (2025: nil) equivalent in the USD Yield account.

The sensitivity to a reasonably possible 1% change in the interest rates, with all other variables held constant would have impacted the profit/loss before tax as follows:

Foreign Currency Risk The Consolidated entity is exposed to foreign currency risk arising from transactions denominated in United States dollars (USD), principally in relation to payments to overseas suppliers and receipts from overseas customers. The Consolidated entity does not enter into forward foreign exchange contracts or other hedging arrangements to manage this exposure. At 30 June 2026 and 30 June 2025, the Consolidated entity had no foreign currency denominated trade payables or trade receivables outstanding. The Consolidated entity's exposure to foreign currency risk at reporting date relates to cash and cash equivalents held in USD operating and Yield accounts, with an AUD equivalent value of $4,156,648 (2025: $nil).

The sensitivity to a reasonably possible 10% movement in the AUD/USD exchange rate, with all other variables held constant, would have impacted profit/(loss) before tax as follows:

Credit risk The Consolidated entity's maximum exposure to credit risk at reporting date is the carrying amount of its financial assets, being cash and cash equivalents and trade receivables.

Liquidity risk Vigilant liquidity risk management requires the Consolidated entity to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The Consolidated entity manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Redemption proceeds from the Yield USD account are ordinarily received within 1–2 business days of a withdrawal request. The Consolidated entity manages liquidity risk on this balance by monitoring it monthly against upcoming committed foreign-currency and operating outflows in accordance with its Foreign Exchange Trading Policy, and by maintaining a threshold above which balances are reviewed for drawdown by the Chief Financial Officer.

The following tables detail the Consolidated entity's remaining contractual maturity for its financial instrument liabilities.

Over 5

Over 5

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

The repayment of the loan in relation to the medical funds is contingent upon the commercial success of the project. This loan is unsecured.

Note 29. Fair Value MeasurementSource: p. 128

The carrying amounts of other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

The fair value of financial liabilities is estimated by discounting the remaining contractual maturities at the current market interest rate that is available for similar financial liabilities.

Note 30. Key Management Personnel DisclosuresSource: p. 128

Compensation The aggregate compensation made to directors and other members of key management personnel of the Consolidated entity is set out below:

Note 31. Remuneration of AuditorsSource: p. 129

All non-audit services disclosed above relate to services performed prior to the Group admission to the ASX on 30 June 2025. No non-audit services were provided by the external auditor following listing.

Note 32. Contingent LiabilitiesSource: p. 129

The Consolidated entity has given the following bank guarantees held as security in relation to lease and credit card facilities:

*The bank guarantee has been provided to the lessor of the Group’s new advanced manufacturing facility as security for the performance of lease obligations. The guarantee may be called upon in the event of non-performance under the lease.

Note 33. CommitmentsSource: pp. 129–130

Capital Commitments - Advanced Manufacturing Facility The Group has entered into contractual arrangements relating to the construction and fit-out of its new advanced manufacturing facility. These commitments are not recognised as liabilities in the financial statements but represent future obligations under contractual arrangements. Payment of all commitments is expected upon completion of the facility which is scheduled for Q2 FY27.

Award Solutions - Construction and Fit-out As at 30 June 2026, the Group had outstanding commitments of approximately $3,575,750 (30 June 2025: $nil) in respect of construction works for the facility.

Kaizen Airconditioning - Mechanical Installation Works As at 30 June 2026, the Group had outstanding commitments of approximately $200,000 (30 June 2025: $nil) in respect of construction works for the facility.

Innavate Integrated Solutions - Workplace Technology Design Services As at 30 June 2026, the Group had outstanding commitments of approximately $264,681 (30 June 2025: $nil) in respect of construction works for the facility.

Allied Scientific Products Pty Ltd - Laboratory equipment As at 30 June 2026, the Group had outstanding commitments of approximately $976,978 (30 June 2025: $nil) in respect of construction works for the facility.

Service Commitments – Research and Development Projects The Group has entered into contractual arrangements for the provision of services relating to research and development projects. These commitments are not recognised as liabilities in the financial statements but represent future obligations under contractual arrangements

Ab Initio Pharma - R&D Project As at 30 June 2026, the Group had outstanding commitments of approximately $250,000 (30 June 2025: $nil) in respect of services to be provided by Ab Initio Pharma under an R & D services agreement.

Note 34. Related Party TransactionsSource: pp. 131–132

Parent Entity Tetratherix Limited is the parent entity.

Subsidiaries Interests in subsidiaries are set out in note 36.

Key Management Personnel Disclosures relating to key management personnel are set out in note 30.

Transactions with Related Parties Transactions with related parties during the current and previous financial year are set out below:

*The Company pays directors' fees of $180,000 (plus GST) per annum, monthly in arrears, to Rothay Advisory, an entity controlled by Emma Cleary, a non-executive director. Directors' fees paid during the year related to the full year ended 30 June 2026 (30 June 2025: six months, reflecting the appointment date). **The Company paid an IPO success fee of $250,000 (plus GST) to Stapleton Ventures, an entity controlled by William Knox, Executive Director, in recognition of executive management's role in completing the Company's IPO. The fee was expensed in the year ended 30 June 2025. The related payable was settled in full during the year ended 30 June 2026 (refer to Payable to related parties below).

Payable to Related Parties The following balances (plus GST) are outstanding at the reporting date in relation to transactions with related parties:

Performance Rights Vesting During the year, 434,028 performance rights held by Cherie Beach, Chief Financial Officer, vested and were issued as ordinary shares to CB & MS Holdings, an entity associated with Cherie Beach, for nil cash consideration. The shares were issued at a fair value of $1,410,591, determined as the market price of the Company's ordinary shares at the vesting date. Refer to Note 25 for issued capital and Note 39 for further information on performance rights.

Application for Shares by Related Parties During the year, related parties applied for shares in the Company, subject to shareholder approval at the Annual General Meeting. Gillian Shea, Director, applied for 6,667 shares at an issue price of $6.00 per share, for total consideration of $40,002. Atlanta Daniel, Director, applied for 329,515 shares at an issue price of $6.00 per share, for total consideration of $1,977,090, via Radar Ventures General Partnership, an entity associated with Atlanta Daniel. As at reporting date, these shares had not been issued pending shareholder approval, and the application monies received are included within share application monies (refer to Note 18).

Loans to/from related parties The following balances are outstanding at the reporting date in relation to loans with related parties:

Terms and conditions All transactions were made on normal commercial terms and conditions and at market rates.

Note 35. Parent Entity InformationSource: pp. 132–133

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries The parent entity has given bank guarantees as at 30 June 2026 of $50,000 (30 June 2025: $25,000) as security against its corporate credit card facility.

Contingent Liabilities The parent entity had no contingent liabilities as at 30 June 2026 and 30 June 2025.

Capital Commitments - Property, Plant and Equipment The parent entity had no capital commitments for property, plant and equipment as at 30 June 2026 and 30 June 2025.

Material Accounting Policy Information The accounting policies of the parent entity are consistent with those of the Consolidated entity, as disclosed in note 2, except for the following: Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. Investments in associates are accounted for at cost, less any impairment, in the parent entity. Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Note 36. Interests in SubsidiariesSource: p. 133

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:

Ownership Interest

Name Principle Place of Business / Country of Incorporation

Note 37. Interests in Joint VenturesSource: pp. 133–134

Interests in joint ventures are accounted for using the equity method of accounting. The joint venture is not considered material to the Group. Information relating to joint venture is set out below:

Ownership Interest

Name Principle Place of Business / Country of Incorporation

In January 2024, the Group entered into a Joint Venture (JV) with Koda Ventures Pty Ltd, each with 50% equity in the company, Tutelix Pty Ltd (Tutelix). Tutelix is a start-up company developing a novel technology that is using a bio stealth hydrogel material, to make radiotherapy treatment safer and more effective. They are currently awaiting TGA approval for distribution.

The interest in joint venture is accounted for using the equity accounting method and had a nil carrying value as at 30 June 2026 (30 June 2025: nil). The Group's share of loss from its JV was not recognised in the current year as the investment has been reduced to nil and the Group has no obligation to fund further losses.

The unrecognised share of losses of the JV for the reporting year was $2,108,754 (2025:$282,329). The cumulative share of losses for the JV for the reporting period was $2,510,142 (2025: $401,387).

Dilution of Interest in Tutelix Pty Ltd

During FY26, Tutelix completed a Series A1 capital raise comprising the issue of 900 new ordinary shares and the conversion of Tutelix's outstanding SAFE notes into 1,049 ordinary shares on completion of the round (refer below). The Consolidated entity did not participate in the round and as a result, the Group's fully diluted ownership interest in Tutelix reduced from 50.00% to 38.92%.

The Group has assessed that it continues to have joint control of Tutelix notwithstanding the reduction in its ownership interest. The shareholders' agreement between the Group and Koda Ventures was not amended by the capital raise, and Tutelix therefore continues to be classified as a joint venture and is equity accounted accordingly. This is a significant judgement, as the Group's ownership interest is below 50%.

The carrying amount of the Group's investment in Tutelix remains nil (2025: nil), as the Group's cumulative share of Tutelix's losses exceeds the carrying amount of its investment.

Carrying Amount and Share of Results

(1) The Group held a 50.00% interest in Tutelix from 1 July 2025 to 10 May 2026, and a 38.92% interest from 11 May 2026 to 30 June 2026, following dilution on completion of the Series A1 capital raise. The Group's share of Tutelix's results for the year has been determined by applying the respective ownership percentage for each period.

SAFE Note Conversion

Tutelix's SAFE (Simple Agreement for Future Equity) notes were classified by Tutelix as financial liabilities measured at fair value through profit or loss under AASB 9. Immediately prior to their conversion into ordinary shares on completion of the Series A1 round, the SAFE notes were remeasured to fair value .This remeasurement gave rise to a loss which was recognised in Tutelix's profit or loss for the period. On conversion, the SAFE liability was derecognised and ordinary share capital was recognised at the same fair value; no further gain or loss arose on conversion.

This remeasurement loss forms part of Tutelix's total comprehensive loss for the period and is reflected, to the extent of the Group's ownership interest, within the Group's share of results disclosed above.

Restrictions, Commitments and Contingent Liabilities

The Group has no commitments relating to its interest in Tutelix, and no significant contingent liabilities relating to this investment, as at 30 June 2026 and 30 June 2025.

Note 38. Cash Flow InformationSource: pp. 135–136

Reconciliation of loss after income tax to net cash used in operating activities

Changes in liabilities arising from financing activities

Note 39. Share-Based PaymentsSource: pp. 136–138

Employee Incentive Program Tetratherix has a Employee Incentive Program (EIP) to provide long-term incentives to employees, including Key Management Personnel (KMP), in the form of performance rights. The EIP is designed to align employee interests with those of shareholders and to support staff retention.

The number of performance rights granted to participants is determined with reference to performance or service criteria. Once granted, the rights are subject to a vesting condition requiring the participant to remain continuously employed by the Group until the relevant vesting date.

Each vested performance right entitles the holder to one ordinary share in the Company. The rights do not carry voting or dividend rights prior to vesting and automatically convert to ordinary shares upon vesting. The rights have no exercise price and no expiry date.

Details of the performance rights granted under the EIP during the year are set out in the table below:

*The fair value of each performance right is equal to the market price of the Company’s ordinary shares at the grant date.

Measurement and Expenses Recognition The performance rights are equity-settled share-based payments. The fair value of the rights granted during the year was determined at the respective grant dates. As the vesting condition comprises continued service only, the fair value of each performance right is equal to the market price of the Company's ordinary shares at grant date. A valuation was also performed using the Black-Scholes option pricing model and no material difference was identified compared to the fair value determined as the market price of the Company's ordinary shares at grant date.

Share-based payment expense is recognised over the vesting period, being the period from the grant date to the vesting date, based on grant date fair value of the rights and number expected to vest. Share based-payment expense recognised for the year ended 30 June 2026 in respect of performance rights issued under the EIP was $2,093,672 (30 June 2025: $464,632). The comparative expense related to the Company's legacy Employee Share Option Plan (ESOP), under which no options remained outstanding as at 30 June 2025.

Key Management Personnel (KMP) Participation Included in the above grants are 520,833 performance rights issued to KMP during the period. These rights are granted under the same EIP as other employees, however may include terms, including vesting periods, specific to individual employees. Refer to note 34 Related Party Transactions.

Equity Issued For Services During the year, the Company issued equity instruments to third-party service providers in satisfaction of services rendered to the Group. These instruments are issued under the Company’s performance right plan for contractors whose services add to shareholder value.

As the fair value of the services received is reliably measurable, these transactions are measured directly at the fair value of the services received, in accordance with AASB 2 Share-based Payment, rather than by reference to the grant-date fair value of the equity instruments issued.

Of the total $126,000 value of services attaching to these arrangements, $43,275 was recognised as an expense for the year ended 30 June 2026 (30 June 2025: $nil), reflecting the proportion of the service period elapsed at reporting date. The remaining $82,725 will be recognised in future periods as the balance of the service period elapses.

*The fair value of each tranche of performances rights is equal to the value of the services that the equity was issued for, rather than grant date market price of the Company’s shares.

Note 40. Earnings Per ShareSource: p. 138

Weighted Average Number of Ordinary Shares Used in Calculating Basic Earnings Per Share

Weighted Average Number of Ordinary Shares Used in Calculating Diluted Earnings Per Share

*As the Group incurred a net loss for the period, potential ordinary shares (including options and performance rights on issue) are anti- dilutive at the balance date, as their inclusion would decrease the loss per share. Accordingly, diluted loss per share is equal to basic loss per share, and potential ordinary shares have been excluded from the calculation of diluted earnings per share in accordance with AASB 133 Earnings per Share.

Note 41. Events After The Reporting PeriodSource: pp. 139–140

There are no matters subsequent to the end of the financial year that may significantly affect the consolidated entity’s operations, the results of those operations, or the Consolidated entity’s state of affairs in future financial years.

Tetratherix Limited Consolidated Entity Disclosure Statement As at 30 June 2026

Tetratherix Technology Pty Limited Body Corporate Australia 100% Australia

Tetratherix Industries Pty Limited Body Corporate Australia 100% Australia

Trimph IP Pty Limited Body Corporate Australia 100% Australia

Tetratherix TLX Pty Limited Body Corporate Australia 100% Australia

Tetratherix BTX Pty Limited Body Corporate Australia 100% Australia

Tetratherix Limited Directors’ Declaration 30 June 2026Source: p. 141

In the directors' opinion:

the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards,

the Corporations Regulations 2001 and other mandatory professional reporting requirements;

the attached financial statements and notes comply with International Financial Reporting Standards as issued

by the International Accounting Standards Board as described in note 2 to the financial statements;

the attached financial statements and notes give a true and fair view of the Consolidated Entity's financial

position as at 30 June 2026 and of its performance for the financial year ended on that date;

there are reasonable grounds to believe that the Company will be able to pay its debts as and when they

become due and payable; and

the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act

2001.

On behalf of the directors

William Knox Director

Dr Ali Fathi Director

DATE 20 August 2026 Sydney

Tetratherix Limited Independent Auditor’s Report 30 June 2026Source: pp. 142–146

Company-supplied content — a structured conversion of the source figure/table, not text extracted from this page.

Independent Auditor’s Report to the Members of Tetratherix Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Tetratherix Limited (the Company and its subsidiaries (the Group)), which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the Directors’ declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the Corporations Act 2001, including:

i) giving a true and fair view of the Group’s financial position as at 30 June 2026 and of its financial performance for the year then ended; and

ii) complying with Australian Accounting Standards and the Corporations Regulations 2001.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the ‘auditor’s responsibilities for the audit of the financial report’ section of our report. We are independent of the Group in accordance with the Corporations Act 2001 and the ethical requirements of the Accounting Professional & Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the Directors of the Company, would be in the same terms if given to the Directors as at the time of this auditor’s report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter

Licence fee revenue

Refer to notes 5 and 19 of the financial report.

During the financial year, the Group entered into a significant licence agreement resulting in the recognition of licence fee revenue of $918,151 during the financial year and contract liabilities of $3,456,570 at 30 June 2026. The accounting for the arrangement was considered a key audit matter due to:

• the complexity in determining the appropriate timing of revenue recognition under AASB 15 Revenue from Contracts with Customers;
• the judgement involved in identifying performance obligations and assessing when the criteria for revenue recognition had been satisfied under the Superpower licence agreement;
• the significance of licence revenue recognised during the year and deferred revenue balances recognised at year end; and
• the significance of the arrangement to the Group's financial performance and financial position.

Grant income – Industry Growth Program and R&D Tax Incentive

Refer to notes 5 and 20 of the financial report.

The Group recognised grant income totalling $2,906,977 during the financial year and deferred income totalling $1,349,606 at 30 June 2026 from the above programs. The accounting for these arrangements was considered a key audit matter due to:

• the judgement involved in determining the appropriate accounting treatment under AASB 120 Accounting for Government Grants and Disclosure of Government Assistance;
• the assessment of whether amounts should be recognised as grant income, deferred

How our audit addressed the key audit matter

Our procedures included, amongst others:

• Obtained and reviewed the licence agreement and assessed management's application of AASB 15 Revenue from Contracts with Customers.
• Evaluated the identification of performance obligations and the timing of satisfaction of those obligations.
• Assessed management's recognition of licence revenue and deferred revenue balances against the contractual terms.
• Tested revenue recognised during the year and agreed key inputs to supporting documentation and cash receipts.
• Assessed the adequacy of the related financial statement disclosures.

Our procedures included, amongst others:

• Obtained and reviewed grant agreements and criteria and assessed management's application of AASB 120 Accounting for Government Grants and Disclosure of Government Assistance.
• Evaluated whether elements of grant funding had been appropriately recognised as income, deferred income, or offset against capitalised development expenditure in accordance with AASB 120 and the Group’s accounting policy.
• Tested grant income recognised during the year and agreed key amounts to supporting documentation and cash receipts.

Key audit matter

income, or offsets against capitalised development expenditure;

• the significance of grant income recognised during the year and deferred grant balances recognised at year end; and
• the significance of these arrangements to the Group's financial performance and financial position.

Capitalisation and recoverability of development costs

Refer to note 16 of the financial report.

As at 30 June 2026, the Group recognised capitalised development costs of $1,125,730 relating to the development of new products.

The capitalisation and recoverability of these development assets was considered a key audit matter due to:

• the judgement involved in determining whether the recognition criteria under AASB 138 Intangible Assets had been satisfied;
• the estimation uncertainty associated with assessing the technical feasibility, commercial viability and future economic benefits of the underlying development projects;
• the complexity of management's assessment of whether indicators of impairment existed and whether the carrying value of the development assets remained recoverable;
• the significance of assumptions used in assessing the expected commercialisation of the products, including regulatory progress, market opportunities and future funding requirements; and
• the significance of the development assets to the Group's financial position.

How our audit addressed the key audit matter

• Assessed the appropriateness of deferred grant income recognised at year end.
• Assessed the adequacy of the related financial statement disclosures.

Our audit procedures included, amongst others:

• Assessed management's application of AASB 138 Intangible Assets in determining whether development expenditure met the criteria for capitalisation.
• Evaluated the technical feasibility of the underlying products through consideration of development milestones, regulatory progress and supporting technical documentation.
• Assessed management's evaluation of the expected future economic benefits of the projects, including consideration of commercialisation plans, market opportunities and available supporting evidence.
• Tested a sample of capitalised development expenditure to supporting documentation and assessed whether the nature of the expenditure met the requirements for capitalisation.
• Evaluated management's assessment of impairment indicators and considered whether the carrying value of the development assets remained recoverable.
• Assessed the adequacy of the related financial statement disclosures.
• Held discussions with management regarding ongoing commercialisation activities, including negotiations with a preferred commercial partner.

Other information

The Directors are responsible for the other information. The other information comprises the information in Tetratherix Limited’s annual report for the year ended 30 June 2026, but does not include the financial report and the auditor’s report thereon. Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information we are required to report that fact. We have nothing to report in this regard.

Directors’ responsibility for the financial report

The Directors of the Company are responsible for the preparation of:

a) the financial report (other than the consolidated entity disclosure statement) that gives a true and

fair view in accordance with Australian Accounting Standards and the Corporations Act 2001; and

b) the consolidated entity disclosure statement that is true and correct in accordance with the

Corporations Act 2001, and

for such internal control as the Directors determine is necessary to enable the preparation of:

i) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and

ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement,

whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibility for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at The Australian Auditing and Assurance Standards Board website at: https://auasb.gov.au/media/bwvjcgre/ar1_2024.pdf. This description forms part of our auditor’s report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 72 to 82 of the Directors’ Report for the year ended 30 June 2026.

In our opinion, the Remuneration Report of Tetratherix Limited for the year ended 30 June 2026, complies with section 300A of the Corporations Act 2001.

Responsibilities

The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Nexia Sydney Audit Pty Ltd

Erin Tanyag Director

Dated: 20 August 2026 Sydney